atopic dermatitis

[Allergy] Scientists give an overview of the clinical picture, and characteristics of the patients as well as the diagnosis and therapy of eczema herpeticum.

[Nature Reviews Immunology] Scientists discuss how the immune responses to dysbiotic microbiota that cross the damaged barrier may be involved in the development of allergic and autoimmune diseases.

[Pfizer Inc. (businesswire)] Pfizer, Inc. announced that the US FDA has extended the priority review period for the New Drug Application for abrocitinib for the treatment of adults and adolescents with moderate to severe atopic dermatitis.

[AbbVie (PRNewswire)] AbbVie announced that the US FDA has extended the review period for the supplemental New Drug Application for upadacitinib in the treatment of adults and adolescents with moderate to severe atopic dermatitis.

[Nature Medicine] The authors investigated the safety and mechanisms of action of Staphylococcus hominis A9, a bacterium isolated from healthy human skin, as a topical therapy for atopic dermatitis.

[European Respiratory Journal] Researchers summarize the current understanding of the biology of type 2 inflammation in asthma, examine its influence on type 2 inflammatory comorbidities, and discuss how type 2 inflammatory biomarkers can be harnessed to further personalise treatments in the age of biologic medicines.